Form D · Biotechnology

Elektrofi, Inc.

Boston, MA · CIK 0001932688

Offering snapshot reported Oct 15, 2024 · SEC filing

Reported sold: $112M
Investors reported: 21
Minimum accepted: $0
First sale: Aug 8, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$96,450,016 → $112,250,024

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 15, 2024	Amendment	$112,250,024	$15,800,008vs Aug 22, 2024	21	SEC filing
Aug 22, 2024	Initial	$96,450,016	No comparison	21	SEC filing
Jun 22, 2022	Initial	$42,535,095	No comparison	23	SEC filing

Offering details

Securities: Equity, Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-522177

Series C Preferred Stock

Source: Form D, filed Oct 15, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Peter Bojo	Director
Constatine Chinoporos	Director
Constantine Chinoporos	Director
Chase Coffman	Director, Executive
Charles L. Cooney	Director
Andrew Goldberg	Director
Arman Gupta	Director
Sam Huang	Director
Noel Jee	Director
Jason Norris	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

25 Drydock Avenue, Second Floor
Boston, MA, 02210